

| |
|----------------------------|
| Reference number(s) |
| 2651-H |

SPECIALTY QUANTITY LIMIT PROGRAM

GALAFOLD (migalastat)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of Fabry disease with an amenable galactosidase alpha gene (GLA) variant fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

| Medication | Standard Limit | FDA-recommended dosing |
|---------------------------------------|----------------|--|
| Galafold (migalastat) 123 mg capsules | 14 per 28 days | 123 mg orally once every other day at the same time of day |

III. REFERENCE

- Galafold [package insert]. Cranbury, NJ: Amicus Therapeutics U.S., Inc.; August 2018.